Clinical Trials Logo

Pulmonary Hypertension clinical trials

View clinical trials related to Pulmonary Hypertension.

Filter by:

NCT ID: NCT05935865 Recruiting - Clinical trials for Pulmonary Hypertension

Monitoring of the Influence of Approved PH-therapies RV-PA Coupling

Start date: February 13, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about the acute (days) changes in right ventricular functions caused by initiation of pharmacological therapies in patients with precapillary pulmonary hypertension. The main question it aims to answer is: • Course of afterload and intrinsic contractility throughout the hospital stay Participants will be equipped with a device for continuous monitoring and recording of the right ventricular pressure signal.

NCT ID: NCT05935605 Recruiting - Clinical trials for Pulmonary Hypertension

Pulmonary Hypertension in Left Heart Disease

Start date: July 20, 2023
Phase:
Study type: Observational

The goal is to compare patients with and without varying severity of pulmonary vascular disease based upon hemodynamic signatures, echocardiographic measures, and lung ultrasound, in tandem with expired gas metabolic testing and blood sampling.

NCT ID: NCT05903001 Recruiting - Asthma Clinical Trials

Diaphragmatic Function as a Biomarker

DFUNBIO
Start date: July 1, 2023
Phase:
Study type: Observational

Dyspnea is among the most common symptoms in patients with respiratory diseases such as Asthma, chronic obstructive pulmonary disease (COPD), Fibrosis, and Pulmonary Hypertension. However, the pathophysiology and underlying mechanisms of dyspnea in patients with respiratory diseases are still poorly understood. Diaphragm dysfunction might be highly prevalent in patients with dyspnea and respiratory diseases. The association of diaphragm function and potential prognostic significance in patients with respiratory diseases has not yet been investigated.

NCT ID: NCT05901168 Recruiting - Clinical trials for Pulmonary Hypertension

Acute Responses of Active Video Games and Traditional Exercise Program in in Patients With Pulmonary Hypertension

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

At least 20 volunteers with a diagnosis of Pulmonary Hypertension in the Department of Cardiology of Dokuz Eylul University and who meet the criteria for follow-up and inclusion will participate in the study. The aim of this study is to examine the acute effects of active video games compared to traditional exercise and the effects on energy expenditure and enjoyment in PD patients. Demographic and clinical information of the participants will be questioned. Active video games and home-based exercise sessions will be held randomly/by the same person with a break of at least 1 day in 1 week, lasting 20 minutes. Heart rate, blood pressure, shortness of breath and oxygen saturation will be measured before and after the sessions. In addition, energy expenditure, heart rate, perceived exertion, shortness of breath and oxygen saturation will be recorded during the sessions. In addition, arterial stiffness will be evaluated with a non-invasive device. At the end of the sessions, whether people like active video games or not will be questioned with a 10-point Likert-type scale.

NCT ID: NCT05896579 Recruiting - COPD Clinical Trials

Identifying Right Ventricular Dysfunction in COPD Through Right Heart Catheterization, Imaging and Exercise

Start date: August 22, 2023
Phase: N/A
Study type: Interventional

This study plans to learn more about heart function among individuals with chronic obstructive pulmonary disease (COPD). In particular, the investigators want to understand the different patterns of right ventricular response to pulmonary hypertension (high pressure in the lungs) during rest and exercise. By identifying patterns of right ventricular dysfunction, this study will help identify better treatments for patients with COPD in the future.

NCT ID: NCT05873387 Recruiting - Clinical trials for Pulmonary Hypertension

Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope

Start date: July 12, 2023
Phase:
Study type: Observational

The major goal of the study is to determine whether phonocardiography (using the Eko DUO stethoscope which can capture a three lead ECG reading) can present features that relate to the presence of PH diagnosed by echocardiography or right heart catheterization (RHC), and therefore have a potential to assist the provider to suspect PH.

NCT ID: NCT05856461 Recruiting - Atrial Fibrillation Clinical Trials

Pulmonary Artery Denervation in Patients With Atrial Fibrillation and Group 2 of Pulmonary Hypertension

PADN+AF
Start date: May 22, 2023
Phase: N/A
Study type: Interventional

The goal of the study is to compare efficacy and safety of the pulmonary artery denervation procedure combined with atrial fibrillation ablation versus atrial fibrillation ablation alone in patients with paroxysmal and persistent atrial fibrillation and group 2 of the pulmonary hypertension

NCT ID: NCT05844462 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease

ERASE PH-COPD
Start date: February 1, 2024
Phase: Phase 3
Study type: Interventional

ERASE PH-COPD is a randomized double-blind study, with 2 parallel groups. Patients with severe pulmonary hypertension due to chronic obstructive pulmonary disease, will be randomly assigned to receive Tadalafil orally or placebo.

NCT ID: NCT05843461 Recruiting - Clinical trials for Pulmonary Hypertension

PIMR and Pulmonary Vascular Disease

Start date: January 10, 2023
Phase:
Study type: Observational

The findings from this innovative, first-in-man, prospective pilot study will elucidate the role of PIMR and RV-IMR in pre-capillary PH. The study cohort will consist of patients with pulmonary pressures ranging from normal (advanced lung disease patients undergoing lung transplant evaluation) to severe PH (PAH and CTEPH patients), and thus will allow for identification of a PIMR cutoff. Participants will include: 1) advanced lung disease patients undergoing bilateral heart catheterization as part of their pre-lung transplant work-up, and 2) newly referred patients to PAH and CTEPH clinics undergoing bilateral heart catheterization as part of standard of care work-up. All participants will undergo PIMR testing, and those with pre-capillary PH will also undergo pulmonary OCT and measurement of RV-IMR. The study seeks to define the relationship between PIMR and PH and to establish the PIMR threshold that identifies pulmonary microvascular dysfunction as well as to evaluate the association of PIMR and pulmonary vascular remodeling on OCT in patients with pre-capillary PH. In addition, the study will assess the relationship between RV-IMR and RV pressure overload among patients with pre-capillary PH.

NCT ID: NCT05827302 Recruiting - Healthy Volunteers Clinical Trials

Integrating ePReBMs From Phoenix in Respiratory Diseases

Start date: October 11, 2023
Phase: N/A
Study type: Interventional

Participants with respiratory disease experience often a worsening of their condition, with increasing symptoms such as cough and shortness of breath. This worsening, often called exacerbation or flare up, impacts on the life of the participants, since they become limited in their daily activities. Healthcare is still based today on limited times for clinical appointments to perform investigations and to meet with specialists/clinicians. Very often, these evaluations do not reflect the way the disease is limiting the patient's life. Wearable devices offer the opportunity to collect data on physical activities and important clinical parameters (such as how the patient is active or just staying in bed during the day), on a daily basis. The HG Phoenix AI- based Smart Watch produced by Health Gauge, an Albertan company based in Edmonton, has the potential to measure heart rate, heart rate variability, blood pressure, pulse wave velocity, respiratory rate, temperature, arterial saturation, sleep pattern (deep, light sleep, awake time), duration and time, daily physical activities (site count and distance) and calories burnt in a simple and non-invasive fashion. Ideally, these parameters could be monitored and recorded 24 hours per 7 days per week. This study aims to demonstrate that this device can be used for a long time at home and it is comfortable to use for the participants, that it is not dangerous and, possibly, that it can help to identify exacerbations before the currently available investigations.